Peripheral oscillometric arterial performance does not depict coronary status in patients with type 2 diabetes mellitus

1. American Diabetes Association . 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S14–s31.
Google Scholar | Crossref | Medline2. Fox, CS, Coady, S, Sorlie, PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham heart study. Circulation 2007; 115: 1544–1550.
Google Scholar | Crossref | Medline | ISI3. Haffner, SM, Lehto, S, Ronnemaa, T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998; 339: 229–234.
Google Scholar | Crossref | Medline | ISI4. Taubert, G, Winkelmann, BR, Schleiffer, T, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 2003; 145: 285–291.
Google Scholar | Crossref | Medline5. Palombo, C, Kozakova, M. Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol 2016; 77: 1–7.
Google Scholar | Crossref | Medline6. Williams, B, Mancia, G, Spiering, W, et al. ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953–2041.
Google Scholar | Crossref | Medline7. Loftus, IM, Naylor, AR, Goodall, S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke A J Cerebral Cir 2000; 31: 40–47.
Google Scholar | Crossref | Medline | ISI8. de Boer, RA, Voors, AA, Muntendam, P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Failure 2009; 11: 811–817.
Google Scholar | Crossref | Medline | ISI9. Baulmann, J, Schillings, U, Rickert, S, et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J Hypertens 2008; 26: 523–528.
Google Scholar | Crossref | Medline | ISI10. Laurent, S, Cockcroft, J, Van Bortel, L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart Journal 2006; 27: 2588–2605.
Google Scholar | Crossref | Medline | ISI11. Vlachopoulos, C, Xaplanteris, P, Aboyans, V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology working group on peripheral circulation: endorsed by the association for research into arterial structure and physiology (ARTERY) society. Atherosclerosis 2015; 241: 507–532.
Google Scholar | Crossref | Medline | ISI12. Visse, R, Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Research 2003; 92: 827–839.
Google Scholar | Crossref | Medline | ISI13. Jaiswal, A, Chhabra, A, Malhotra, U, et al. Comparative analysis of human matrix metalloproteinases: Emerging therapeutic targets in diseases. Bioinformation 2011; 6: 23–30.
Google Scholar | Crossref | Medline14. Barondes, SH, Castronovo, V, Cooper, DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell; 76: 597–598.
Google Scholar15. Dumic, J, Dabelic, S, Flogel, M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760(4): 616–635.
Google Scholar | Crossref | Medline | ISI16. Menini, S, Iacobini, C, Blasetti Fantauzzi, C, et al. Role of galectin-3 in obesity and impaired glucose homeostasis. Oxi Med Cell Long 2016; 2016: 9618092.
Google Scholar | Crossref | Medline | ISI17. Henderson, NC, Sethi, T. The regulation of inflammation by galectin-3. Immu Rev 2009; 230: 160–171.
Google Scholar | Crossref | Medline | ISI18. Nachtigal, M, Al-Assaad, Z, Mayer, EP, et al. Galectin-3 expression in human atherosclerotic lesions. Am J Path 1998; 152: 1199–1208.
Google Scholar | Medline | ISI19. Calvier, L, Miana, M, Reboul, P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterio Thromb Vas Bio 2013; 33: 67–75.
Google Scholar | Crossref | Medline | ISI20. Horvath, IG, Nemeth, A, Lenkey, Z, et al. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J Hypertens 2010; 28: 2068–2075.
Google Scholar | Crossref | Medline | ISI21. Arterial Stiffness Collaboration . Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. Eur Heart J 2010; 31: 2338–2350.
Google Scholar | Crossref | Medline22. Cacoub, PP, Bhatt, DL, Steg, PG, et al. Patients with peripheral arterial disease in the charisma trial. Eur Heart J 2009; 30: 192–201.
Google Scholar | Crossref | Medline | ISI23. Shore, AC, Colhoun, HM, Natali, A, et al. Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study. J Intern Med 2015; 278: 291–302.
Google Scholar | Crossref | Medline24. Ferretti, G, Bacchetti, T, Banach, M, et al. Impact of statin therapy on plasma MMP-3, MMP-9, and TIMP-1 concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Angiology 2017; 68: 850–862.
Google Scholar | SAGE Journals | ISI25. Kuliczkowski, W, Banaszkiewicz, M, Mysiak, A, et al. Does arterial hypertension affect plasma levels of matrix metalloproteinases and their tissue inhibitors in patients with stable coronary artery disease? A preliminary study. Cardiol Res Pract 2019; 2019: 6921315.
Google Scholar | Crossref | Medline26. Loftus, IM, Naylor, AR, Bell, PR, et al. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002; 89: 680–694.
Google Scholar | Crossref | Medline | ISI27. Vlachopoulos, C, Aznaouridis, K, Dima, I, et al. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Card 2007; 122: 232–238.
Google Scholar | Crossref | Medline | ISI28. Yasmin, McEniery, CM, Wallace, S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterios Thromb Vas Bio 2005; 25: 372.
Google Scholar | Crossref | Medline | ISI29. Papazafiropoulou, A, Perrea, D, Moyssakis, I, et al. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Its Comp 2010; 24: 20–27.
Google Scholar | Crossref | Medline30. Libhaber, E, Woodiwiss, AJ, Raymond, A, et al. Independent associations of circulating galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample. Hypertension 2015; 65: 1356–1364.
Google Scholar | Crossref | Medline | ISI31. Lorenzo-Almorós, A, Pello, A, Aceña, Á, et al. Galectin-3 is associated with cardiovascular events in post-acute coronary syndrome patients with type-2 diabetes. J Clin Med 2020; 9(4): 1105.
Google Scholar | Crossref

留言 (0)

沒有登入
gif